The companies expect the deal to close in the fourth quarter. MyoKardia's lead drug candidate is mavacamten, which it is developing for hypertrophic cardiomyopathy and plans to submit to the FDA in the first quarter of next year.
Bay Area startup MyoKardia just filed for an IPO with the SEC for its precision medicine approach to genetic heart disease. Specifically, it's developing small molecule drugs to treat cardiomyopathies.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
San Francisco startup MyoKardia just closed a $46 million Series B for its precision medicine approach to genetic heart disease. The startup’s studying the genetic root cause of hypertrophic and dilated cardiomyopathies – defects which result in the thickening or weakening off heart tissues, respectively. The funding will help advance its lead drug candidate, MYK-461, which is in […]